Milestone Scientific - Advanced Injection Technology

CompuMed ^® Instrument

» Product Description
» Our Distributors

CompuFlo^® System
Applications in Research
and Development

» Epidurals

» Intra-Articular Injections

» Self Injections

» Neurosurgical

» Ophthalmic Surgery

» Dermal Filler/Cosmetic

Osteoarthritis is reported to affect 13.9% of all adults, aged 25 and older; and 33.6% of those over the age of 65. In the US alone, an estimated 21 million Americans suffering from Osteoarthritis receive intra-articular injections on an annual basis, and that number is projected to climb due to:

the aging of the population;
the increasing rate of obesity;
the trend towards lifelong physical and recreational activity;
the rise in population of systemic degenerative diseases;
the development of pharmaceutical agents that are proving to be effective alternative to surgical join treatment or replacement; and
growth in the scientific evidence supporting intra-articular injections as a responsible treatment modality of the pathologic joint space.

In 2007, an in-vivo animal clinical study led by Thomas D. Morris, Inc., a nationally recognized and respected animal research team, set out to evaluate whether use of the CompuFlo^®-based system could accurately identify the intra-articular space. The conclusions were:

The CompuFlo-based system demonstrated an ability to accurately identify anatomic structures of ligament, tendon, muscle, meniscus, cartilage and intra-articular space.
Use of fluoroscopy visually confirmed the delivery system’s ability to locate and deliver solution specifically to an intra-articular joint in an animal model.
The CompuFlo-based system was found to have multiple benefits in comparison to conventional syringe injection techniques, including superior tactile control, greater ease of use and improved reliability and accuracy of intra-articular injections.